Page last updated: 2024-09-05

sorafenib and Stomach Neoplasms

sorafenib has been researched along with Stomach Neoplasms in 27 studies

Research

Studies (27)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (14.81)	29.6817
2010's	17 (62.96)	24.3611
2020's	6 (22.22)	2.80

Authors

Authors	Studies
Cai, S; Cheng, Y; Fang, J; Fu, S; Yuan, X; Zhang, W	1
Fang, Z; Li, Y; Lu, Y; Wang, H; Wang, M; Wu, Y; Xu, X	1
Chung, IJ; Hong, YS; Kang, WK; Kang, YK; Kim, YH; Lee, KH; Nam, BH; Park, YI; Park, YS; Ryoo, BY; Ryu, MH; Shen, L; Shin, DB; Yang, SH; Yeh, KH; Yoo, C; Zang, DY	1
Abad, M; Al-Abdulla, R; Briz, O; Bujanda, L; Herraez, E; Lozano, E; Macias, RIR; Marin, JJG; Perez-Silva, L; Segues, N	1
Chen, J; He, ML; Huo, X; Wang, C; Zhao, T	1
Ai, Y; Gong, N; Huang, Y; Ju, Z; Li, J; Lu, G; Wu, X; Wu, Y; Xiang, D; Yang, J; Yang, Z; Zeng, B	1
Bo, LS; Ke, WB; Li, T; Meng, YP; Zhang, Y	1
Li, A; Liu, H; Yang, F; Zhang, H	1
Feng, X; Tang, X; Wu, X; Xu, X	1
Fuse, N; Hashizume, K; Ito, Y; Kato, K; Kiyota, N; Kuroki, Y; Minami, H; Ohtsu, A; Yamada, Y	1
Barnadas, A; Barriuso, J; Casado, E; Gallego, R; Garcia Foncillas, J; Garcia-Albeniz, X; Iranzo, V; Juez, I; Martin-Richard, M; Maurel, J; Pericay, C; Queralt, B; Saigi, E; Visa, L	1
Bao, X; Chen, J; He, X; Li, Y; Niu, B; Yu, H; Zhang, Z; Zhu, J	1
En, LM; Hao, L; Ju, H; Juan, LW; Kai, HY	1
Chen, S; Lin, H; Tao, C	1
Huang, YS; Xue, Z; Zhang, H	1
Berger, M; Bouvier, N; Capanu, M; Herrera, JM; Ilson, DH; Janjigian, YY; Ku, GY; Socci, ND; Tang, LH; Vakiani, E; Viale, A	1
Cai, J; Wang, KL; Yang, YC; Yin, J; Zhang, J; Zhang, ZT	1
Ni, Y; Tian, J; Wang, H; Wang, W; Yao, Z; Ye, L	1
Aburatani, H; Hirakawa, K; Iwata, C; Johansson, E; Kano, MR; Kiyono, K; Komuro, A; Matsumoto, Y; Miyazono, K; Miyoshi, H; Morishita, Y; Shirai, YT; Suzuki, HI; Watanabe, A; Yashiro, M	1
Chong, LW; Chow, P; Chung, A; Huynh, H; Koong, HN; Lam, WL; Lee, J; Lee, SS; Lew, GB; Ngo, VC; Ong, HS; Ong, WJ; Soo, KC; Thng, CH; Yang, S	1
Amadori, D; Arienti, C; Brigliadori, G; Fabbri, F; Leonetti, C; Passardi, A; Scarsella, M; Silvestrini, R; Tesei, A; Ulivi, P; Zoli, W; Zupi, G	1
Altorki, NK; Alvarez, H; Beer, DG; Boonstra, JJ; Chaves, P; Darnton, SJ; Dinjens, WN; Eshleman, JR; Klimstra, DS; Lin, L; Pereira, AD; Ribeiro, C; Roque, L; Schrump, DS; Shimada, Y; Tang, LH; Tilanus, HW; van Dekken, H; van Marion, R	1
Ansari, RH; Benson, AB; Catalano, P; O'Dwyer, PJ; Powell, M; Sun, W	1
Chang, HM; Choi, YH; Kang, BW; Kang, YK; Kim, C; Kim, TW; Lee, JL; Ryu, MH	1
George, S; Hornick, JL; Jagannathan, JP; Ramaiya, NH; Shinagare, AB	1
Hampton, T	1
Di Fiore, F; Michel, P	1

Trials

6 trial(s) available for sorafenib and Stomach Neoplasms

Article	Year
Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE). Cancer medicine, 2023, Volume: 12, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease Progression; Humans; Sorafenib; Stomach Neoplasms; Treatment Outcome	2023
A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2014, Volume: 17, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Niacinamide; Oxonic Acid; Patient Compliance; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Tegafur; Treatment Outcome	2014
Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. Investigational new drugs, 2013, Volume: 31, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Treatment Outcome	2013
Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. PloS one, 2015, Volume: 10, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Survival Analysis	2015
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jun-20, Volume: 28, Issue:18 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisplatin; Docetaxel; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome	2010
Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Investigational new drugs, 2012, Volume: 30, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Republic of Korea; Sorafenib; Stomach Neoplasms; Time Factors; Treatment Outcome	2012

Other Studies

21 other study(ies) available for sorafenib and Stomach Neoplasms

Article	Year
SIRT6 silencing overcomes resistance to sorafenib by promoting ferroptosis in gastric cancer. Biochemical and biophysical research communications, 2021, 11-05, Volume: 577 Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Ferroptosis; Gene Expression Regulation, Neoplastic; Humans; Kelch-Like ECH-Associated Protein 1; NF-E2-Related Factor 2; Phospholipid Hydroperoxide Glutathione Peroxidase; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Sirtuins; Sorafenib; Stomach Neoplasms	2021
Increased ATF2 expression predicts poor prognosis and inhibits sorafenib-induced ferroptosis in gastric cancer. Redox biology, 2023, Volume: 59 Topics: Activating Transcription Factor 2; Animals; Cell Line, Tumor; Disease Models, Animal; Ferroptosis; Humans; Phenotype; Sorafenib; Stomach Neoplasms	2023
Sensitizing gastric adenocarcinoma to chemotherapy by pharmacological manipulation of drug transporters. Biochemical pharmacology, 2020, Volume: 171 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Cell Line, Tumor; Diclofenac; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Male; Mice, Nude; Middle Aged; Multidrug Resistance-Associated Proteins; Sorafenib; Stomach Neoplasms; Xenograft Model Antitumor Assays	2020
Pterostilbene enhances sorafenib's anticancer effects on gastric adenocarcinoma. Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:21 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Death; Cell Line, Tumor; Cell Shape; Cell Survival; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Male; Mice, Inbred BALB C; Mice, Nude; Sorafenib; Stilbenes; Stomach Neoplasms; Xenograft Model Antitumor Assays	2020
The impact of recent chemotherapy on immunity in 2 COVID-19 cases with gastrointestinal tumors: A case report. Medicine, 2021, May-28, Volume: 100, Issue:21 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Cyclobutanes; Docetaxel; Drug Therapy, Combination; Humans; Liver Neoplasms; Lung; Male; Middle Aged; Organoplatinum Compounds; RNA, Viral; SARS-CoV-2; Sorafenib; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Outcome	2021
miR-542-3p Appended Sorafenib/All-trans Retinoic Acid (ATRA)-Loaded Lipid Nanoparticles to Enhance the Anticancer Efficacy in Gastric Cancers. Pharmaceutical research, 2017, Volume: 34, Issue:12 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Mice, Nude; MicroRNAs; Nanoparticles; Niacinamide; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Tretinoin	2017
Gastric cancer combination therapy: synthesis of a hyaluronic acid and cisplatin containing lipid prodrug coloaded with sorafenib in a nanoparticulate system to exhibit enhanced anticancer efficacy and reduced toxicity. Drug design, development and therapy, 2018, Volume: 12 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cell Survival; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Hyaluronic Acid; Lipids; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Nanoparticles; Particle Size; Polyethylene Glycols; Prodrugs; Sorafenib; Stomach Neoplasms; Structure-Activity Relationship; Surface Properties; Tumor Cells, Cultured	2018
Biosynthesis of sorafenib coated graphene nanosheets for the treatment of gastric cancer in patients in nursing care. Journal of photochemistry and photobiology. B, Biology, 2019, Volume: 191 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Graphite; Humans; Nanostructures; Nursing Care; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sorafenib; Stomach Neoplasms	2019
The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer. Biomaterials, 2014, Volume: 35, Issue:15 Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Drug Carriers; Humans; Lipids; Mice; Mice, Inbred BALB C; Mice, Nude; Nanodiamonds; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Stomach; Stomach Neoplasms	2014
Sorafenib regulating ERK signals pathway in gastric cancer cell. Environmental toxicology and pharmacology, 2014, Volume: 38, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Microcystis; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Sorafenib; Stomach Neoplasms	2014
The regulation of ERK and p-ERK expression by cisplatin and sorafenib in gastric cancer cells. Gene, 2014, Nov-15, Volume: 552, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; G1 Phase Cell Cycle Checkpoints; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Resting Phase, Cell Cycle; Sorafenib; Stomach Neoplasms	2014
Sorafenib reverses resistance of gastric cancer to treatment by cisplatin through down-regulating MDR1 expression. Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:2 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Cell Line, Tumor; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Xenograft Model Antitumor Assays	2015
Heparin-functionalized Pluronic nanoparticles to enhance the antitumor efficacy of sorafenib in gastric cancers. Carbohydrate polymers, 2016, Jan-20, Volume: 136 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Female; Heparin; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Niacinamide; Phenylurea Compounds; Poloxamer; Sorafenib; Stomach Neoplasms	2016
DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:7 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; HCT116 Cells; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Stomach Neoplasms; Tumor Burden	2016
Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling. Journal of the National Cancer Institute, 2009, Apr-15, Volume: 101, Issue:8 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Disease Progression; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Immunohistochemistry; Lentivirus Infections; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Phosphorylation; Protein Serine-Threonine Kinases; Pyridines; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Signal Transduction; Smad2 Protein; Sorafenib; Stomach Neoplasms; Thrombospondin 1; Transforming Growth Factor beta; Transplantation, Heterologous; Vascular Endothelial Growth Factor A	2009
AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. Molecular cancer therapeutics, 2009, Volume: 8, Issue:9 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Blotting, Western; Disease Models, Animal; Drug Synergism; Humans; Mice; Mice, SCID; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms	2009
Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. Journal of cellular and molecular medicine, 2011, Volume: 15, Issue:2 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Mitosis; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Rhodamines; Sorafenib; Stomach Neoplasms; Taxoids; Xenograft Model Antitumor Assays	2011
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. Journal of the National Cancer Institute, 2010, Feb-24, Volume: 102, Issue:4 Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Biomedical Research; Carcinoma; Carcinoma, Large Cell; Cell Line, Tumor; Clinical Trials as Topic; Colorectal Neoplasms; DNA Fingerprinting; Esophageal Neoplasms; Humans; Lung Neoplasms; National Institutes of Health (U.S.); Niacinamide; Oligonucleotides; Oligopeptides; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Stomach Neoplasms; Tandem Repeat Sequences; Telomerase; United States	2010
Intracranial metastasis from pediatric GI stromal tumor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Apr-01, Volume: 30, Issue:10 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Brain Neoplasms; Drug Administration Schedule; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Stomach Neoplasms; Sunitinib; Treatment Outcome	2012
Cancer drug trials show modest benefit: drugs target liver, gastric, head and neck cancers. JAMA, 2007, Jul-18, Volume: 298, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Cetuximab; Clinical Trials, Phase III as Topic; Drug Combinations; Head and Neck Neoplasms; Humans; Liver Neoplasms; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms; Tegafur	2007
[News in digestive oncology]. Bulletin du cancer, 2008, Volume: 95, Issue:1 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardia; Colonic Neoplasms; Combined Modality Therapy; Digestive System Neoplasms; Esophageal Neoplasms; Humans; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms	2008